Drug Trial Radar · NCT07178249
Evaluating the Safety and Preliminary Efficacy of EXG202 Gene Therapy for Neovascular AMD
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 16, 2025
Primary completion
Feb 28, 2028
Study completion Dec 30, 2032
Sponsor
- Lead sponsor
- Guangzhou Jiayin Biotech LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VEGF inhibitors (anti-VEGF),such as aflibercept has been shown to be safe and effective for treating nAMD and have demonstrated improvement in vision. However, anti-VEGF therapy is administered frequently via intravitreal injection and can be a significant burden to the patients. EXG 202 is a recombinant adeno-associated virus (rAAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein. The long-term, stable delivery of this therapeutic protein following a 1 time gene therapy treatment for nAMD could potentially reduce the treatment burden of currently available therapies while maintaining vision with a favorable benefit.
Conditions
- Wet Age-related Macular Degeneration
Interventions
EXG202 injectionBiological
EXG202 injection is a gene therapy product for the treatment of wet (neovascular) Age-related Macular Degeneration(wAMD) with a single intravitreal injection and administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability after EXG202 injectionTime frame: Up to 52 weeks after treatment
- Preliminary Efficancy after EXG202 injectionTime frame: Up to 52 weeks after treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.